Affiliations: The Nordic Cochrane Centre, Department 7811, Rigshospitalet, Blegdamsvej, Copenhagen, Denmark | Department of Pharmacy, Faculty of Health and Medical Sciences, Section for Social and Clinical Pharmacy, University of Copenhagen, Copenhagen, Denmark
Note: [] Address for correspondence: Margrethe Nielsen, The Nordic Cochrane Centre, Rigshospitalet, Department 7811, DK-2100 Copenhagen, Denmark. E-mail: [email protected]
Abstract: AIM: Our objective was to explore communications from drug agencies about benzodiazepine dependence and selective serotonin reuptake inhibitors (SSRIs) withdrawal reactions over time. METHODS: Documentary study. We searched the web-sites of the European Medicines Agency and the drug agencies in USA, UK, and Denmark for documents mentioning benzodiazepines or SSRIs. We supplemented with other relevant literature that could contribute to our study. The searches were performed in 2009 in PubMed, Google, BMJ and JAMA. RESULTS: It took many years before the drug regulators acknowledged benzodiazepine dependence and SSRI withdrawal reactions and before the prescribers and the public were informed. Drug regulators relied mainly on the definitions of dependence and withdrawal reactions from the diagnostic psychiatric manuals, which contributed to the idea that SSRIs do not cause dependence, although it is difficult for many patients to stop treatment. In the perspective of a precautionary principle, drug agencies have failed to acknowledge that SSRIs can cause dependence and have minimised the problem with regard to its frequency and severity. In the perspective of a risk management principle, the drug agencies have reacted in concordance with the slowly growing knowledge of adverse drug reactions and have sharpened the information to the prescribers and the public over time. However, solely relying on spontaneous reporting of adverse effects leads to underestimation and delayed information about the problems. CONCLUSION: Given the experience with the benzodiazepines, we believe the regulatory bodies should have required studies from the manufacturers that could have elucidated the dependence potential of the SSRIs before marketing authorization was granted.
Keywords: SSRI, benzodiazepine, dependence, withdrawal reaction, drug regulators
